Systemic sclerosis associated pulmonary hypertension: Improved survival in the current era

Heart

Volumn 92, Issue 7, 2006, Pages 926-932

  Williams, M H ^a   Das, C ^a   Handler, C E ^a   Akram, M R ^a   Davar, J ^a   Denton, C P ^a   Smith, C J ^b   Black, C M ^a   Coghlan, John G ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ILOPROST; LOOP DIURETIC AGENT; NIFEDIPINE; PROSTACYCLIN; PROSTANOID; SPIRONOLACTONE; UNIPROST; WARFARIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG USE; FEMALE; HEART CATHETERIZATION; HEART FUNCTION; HEART HEMODYNAMICS; HUMAN; INFORMATION PROCESSING; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SCLEROSIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS; WALKING; WORLD HEALTH ORGANIZATION;

EID: 33745637694     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.069484     Document Type: Article

References (28)

1. Rich S, Rubin LJ, Abenhail L, et al. Executive summary from the world symposium on primary pulmonary hypertension (Evian, France, September 6-10, 1998). http://www.who.int/ned/cvd/pph.html (accessed 1 Feb 2002).
2. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-50.
3. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cordiol 2004;43:25S-32S.
4. Laughlin W, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
5. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000;132:425-34.
6. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
7. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
8. Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogues on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002;26:194-201.
9. Channick RN, Sitbon O, Barst RJ, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:62S-7S.
10. Shi-Wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodelling: role of endothelin-1. J Invest Dermatol 2001;116:417-25.
11. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
12. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
13. Abraham DJ, Vanccheeswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997;151:831-41.
14. Kadono T, Kikuchi K, Sato S, et al. Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 1995;287:439-42.
15. Yamane K, Miyauchi T, Suzuki N, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1994;21:1268-76.
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
17. Rubin U, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
18. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
19. Simonneau G, Barst R J, Galiè N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind randomized controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
20. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
21. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
22. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
23. Collett D. Modelling survival data in medical research, London; Chapman and Hall, 1994.
24. Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving prostacyclin. Am J Respir Crit Care Med 2003;167:580-6.
25. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary hypertension. J Am Coll Cardiol 2004;43(suppl S):13S-24S.
26. Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension. In: Rubin L, Rich S, eds. Primary pulmonary hypertension. New York: Marcel Dekker, 1997:83-129.
27. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;4:780-8.
28. Koh ET, Lee P, Gladman DD, et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.